Sassolas G, Serusclat P, Claustrat B, Trouillas J, Merabet S, Cohen R, Souquet J C
Centre de Médecine Nucléaire, Hôpital Neuro-Cardiologique, Lyon, France.
Horm Res. 1988;29(2-3):124-8. doi: 10.1159/000180987.
The effect os SMS 201-995 (Sandostatin), a long-acting somatostatin analog, on different types of pituitary adenomas including alpha-subunit elevation is illustrated in this report. Treatment induced a fall in hCG levels in a woman with a pituitary adenoma producing only alpha-subunit. In 3 acromegalic patients, there was only a partial drop in GH and alpha-hCG. The same effect was observed in a woman with menopausal FSH and LH levels. SMS reduced plasma TSH and alpha-hCG in a case of thyrotropic adenoma. Two patients exhibiting FSH- and alpha-hCG-secreting adenomas did not respond to acute administration of SMS 201-995. More patients have to be treated before a definitive statement can be made on the usefulness of somatostatin analogs in the management of different types of pituitary adenomas.
本报告阐述了长效生长抑素类似物SMS 201-995（善得定）对不同类型垂体腺瘤的影响，包括α亚基升高情况。治疗使一名仅产生α亚基的垂体腺瘤女性患者的hCG水平下降。在3例肢端肥大症患者中，GH和α-hCG仅出现部分下降。在一名绝经后FSH和LH水平的女性患者中观察到了相同效果。在一例促甲状腺素腺瘤患者中，SMS降低了血浆TSH和α-hCG。两名表现为分泌FSH和α-hCG腺瘤的患者对急性给予SMS 201-995无反应。在能够对生长抑素类似物在不同类型垂体腺瘤治疗中的效用做出明确结论之前，还需要治疗更多患者。
